Message #18 From:
NewsBot Date: November 15, 2006 01:43:00 PM
AVNR News AVANIR Pharmaceuticals Invites Investors to Listen to the Lazard Capital Markets 3rd Annual Life Sciences Conference Webcast
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) will be presenting at Lazard
Capital Markets 3rd Annual Life Sciences
Conference on Tuesday, November 28, 2006 at 8:30 a.m. ET in New York,
New York. AVANIR’s Senior Vice President of
Sales and Marketing, Keith Katkin, will be presenting at the investor
conference.
The presentation will be available via a live webcast accessible through
AVANIR’s corporate website at www.avanir.com.
To access the webcast, log on to AVANIR’s site
fifteen minutes prior to the presentation to register and download any
necessary audio software. An archive of the presentation will be
available for 90 days following the event.
About AVANIR
AVANIR Pharmaceuticals is focused on developing, acquiring and
commercializing novel therapeutic products for the treatment of chronic
diseases. AVANIR’s products and product
candidates address therapeutic markets that include the central nervous
system, cardiovascular disorders, inflammation and infectious diseases.
AVANIR currently markets FazaClo®,
the only orally-disintegrating formulation of clozapine for the
management of severely ill schizophrenic patients who fail to respond
adequately to standard schizophrenic drug treatments. FazaClo is also
indicated for reducing the risk of suicidal behavior in patients with
schizophrenic or schizoaffective disorder. For full prescribing
information and important safety information regarding FazaClo, please
visit www.fazaclo.com. Zenvia™,
AVANIR's lead product candidate for the treatment of involuntary
emotional expression disorder (IEED), is the subject of an approvable
letter from the FDA and future development plans for this product
candidate are under consideration. The Company does not know at this
time what impact, if any, the ongoing discussions with the FDA for IEED
may have on the development of Zenvia for other indications.
Additionally, AVANIR has completed the patient recruitment in a Phase
III clinical trial with Zenvia as a potential treatment for patients
with painful diabetic neuropathy. AVANIR has active collaborations with
two international pharmaceutical companies: Novartis International
Pharmaceutical Ltd. for the treatment of inflammatory disease and
AstraZeneca for the treatment of cardiovascular disease. The Company's
first commercialized product, abreva®,
is marketed in North America by GlaxoSmithKline Consumer Healthcare and
is the leading over-the-counter product for the treatment of cold sores.
Further information about AVANIR can be found at www.avanir.com.
